Morgan Stanley: Sinopharm Group (01099.HK) Q3 results reflect that the domestic industry is still under pressure; maintains "Overweight" rating with a target price of HK$22.5

Zhitong Finance APP has learned that Morgan Stanley issued a research report stating it maintains a "Overweight" rating and a target price of HK$22.5 for Sinopharm Group (01099.HK). The bank noted that the company's third-quarter 2026 results reflect that the domestic pharmaceutical industry is still under pressure, with hospital reimbursement controls and price cuts continuing to drag on revenue and profit margins.